

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
KOSTENIS, et al.

Examiner: Not Yet Known

Art Unit: Not Yet Known

Application No.: **Not Yet Known**

Filed: **November 12, 2003**

Title: **USE OF EDG2 RECEPTOR IN AN
ANIMAL MODEL OF HEART
FAILURE**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

12 November 2003

Date of Deposit

Signature

EL 964841864 US

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,



F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0083 US NP